Cargando…

The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive

PURPOSE: To identify novel oncogenic mutations in non-small cell lung cancer patient specimens that lack mutations in known targetable genes (“pan-negative” patients). METHODS: Comprehensive mutational analyses were performed on 1,356 lung adenocarcinoma specimens. In this cohort of patients, common...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Su, Zhang, Yang, Pan, Yunjian, Cheng, Chao, Sun, Yihua, Chen, Haiquan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602469/ https://www.ncbi.nlm.nih.gov/pubmed/28979142 http://dx.doi.org/10.2147/OTT.S131999

Ejemplares similares

Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
por: Li, Hang, et al.
Publicado: (2014)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis
por: Zheng, Shanbo, et al.
Publicado: (2016)

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
por: Wang, Rui, et al.
Publicado: (2015)

Sequential treatment of tyrosine kinase inhibitors and chemotherapy for EGFR-mutated non-small cell lung cancer: a meta-analysis of Phase III trials
por: Zhang, Yiliang, et al.
Publicado: (2013)

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
por: Cheng, Chao, et al.
Publicado: (2015)

Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR
por: Wagner, Anja, et al.
Publicado: (2022)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Zinc finger protein 277 is an intestinal transit-amplifying cell marker and colon cancer oncogene
por: Xie, Guofeng, et al.
Publicado: (2022)

The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis
por: Wang, Lei, et al.
Publicado: (2014)

Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma
por: Hu, Haichuan, et al.
Publicado: (2014)

Health Tract, No. 277: The Tomatoe
Publicado: (1867)

Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
por: Greulich, Heidi, et al.
Publicado: (2005)

EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2018)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

EGFR mutations in sinonasal squamous tumors: oncogenic and therapeutic implications
por: Udager, Aaron M., et al.
Publicado: (2015)

Correction: EGFR C797S, EGFR T790M and EGFR sensitizing mutations in non-small cell lung cancer revealed by six-color crystal digital PCR
por: Madic, Jordan, et al.
Publicado: (2019)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
por: Chen, Yang, et al.
Publicado: (2018)

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
por: Li, Chenguang, et al.
Publicado: (2011)

201909-277 OpenDays ME-31
por: Ordan, Julien Marius, et al.
Publicado: (2019)

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations
por: Zheng, Difan, et al.
Publicado: (2016)

Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2
por: Bae, Kieun, et al.
Publicado: (2022)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
por: Chen, Jianxin, et al.
Publicado: (2022)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
por: Costa, Daniel B, et al.
Publicado: (2007)

Preliminary Discovery of Small Molecule Inhibitors of Epidermal Growth Factor Receptor (EGFR) That Bind to the Extracellular Domain
por: Di Liddo, Rosa, et al.
Publicado: (2022)

Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
por: Zhang, Shirong, et al.
Publicado: (2015)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

ZNF277 microdeletions, specific language impairment and the meiotic mismatch methylation (3M) hypothesis
por: Pembrey, Marcus, et al.
Publicado: (2015)

277 Molecular Epidemiology of Staphyloccocus aureus in Children with Bacteremia
por: Al-Zubeidi, Duha, et al.
Publicado: (2014)

SUN-277 Severe Hyperglycemia in the Setting of Hypernatremic Dehydration
por: Gupta, Meenal, et al.
Publicado: (2019)

SAT-277 A Fierce Presentation of Cushing Disease
por: Al Sabie, Farah Laith, et al.
Publicado: (2020)

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations
por: Wang, Jia-li, et al.
Publicado: (2022)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Efficacy of erlotinib in NSCLC harboring rare EGFR extracellular domain mutation (T263P) and common mutations: Case report and literature review
por: Wang, Qian, et al.
Publicado: (2022)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
por: Yoshimura, Akihiro, et al.
Publicado: (2018)

Clinical analysis of sixty‐four patients with T1aN2M0 stage non‐small cell lung cancer who had undergone resection
por: Xiong, Jian, et al.
Publicado: (2015)

Autophosphorylation of the carboxyl‐terminal domain is not required for oncogenic transformation by lung‐cancer derived EGFR mutants
por: Cho, Jeonghee, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ueo1j77d3go99qqsh0okam1ajn